<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02337712</url>
  </required_header>
  <id_info>
    <org_study_id>2014-FXY-037</org_study_id>
    <nct_id>NCT02337712</nct_id>
  </id_info>
  <brief_title>Once-daily Simultaneous Modulated Accelerated Thoracic Radiotherapy in Limited Small-cell Lung Cancer</brief_title>
  <official_title>Once-daily Simultaneous Modulated Accelerated Thoracic Radiotherapy Compared With Twice-daily Radiotherapy in Limited Small-cell Lung Cancer Treated Concurrently With Cisplatin and Etoposide</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sun Yat-sen University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sun Yat-sen University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This Phase II randomized study is to determine whether once-daily simultaneous modulated
      accelerated thoracic radiotherapy (RT) resulted in better survival than twice-daily RT for
      patients with limited-stage small-cell lung cancer (LD-SCLC).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This Phase II randomized study is to determine whether once-daily (qd)simultaneous modulated
      accelerated thoracic radiotherapy resulted in better survival than twice-daily(bid) RT for
      patients with limited-stage small-cell lung cancer (LD-SCLC).

      All patients received four cycles of etoposide and cisplatin (EP), each of 3 days' duration
      and separated by 21 days. Thoracic RT was initiated at the first or second chemotherapy. Qd
      RT includes the delivery of 65 Gy in 26 fractions delivered on weekdays for a total of 33
      days. Bid RT includes the delivery of 45 Gy in 30 fractions delivered on weekdays for a total
      of 19 days. After the chest RT and the fourth cycle of EP, prophylactic cranial irradiation
      is administered to all patients with a complete remission. 204 patients are needed to be
      enrolled for an 80% power to detect an improvement in 3-year progression-free survival rate
      from the expected 25% to 40%.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>January 2015</start_date>
  <completion_date type="Anticipated">December 2020</completion_date>
  <primary_completion_date type="Anticipated">December 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>progression-free survival</measure>
    <time_frame>3-year</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">204</enrollment>
  <condition>Small Cell Lung Cancer</condition>
  <arm_group>
    <arm_group_label>q.d. RT</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>q.d. RT (65 Gy in 26 fractions) to the chest and four cycles of etoposide and cisplatin</description>
  </arm_group>
  <arm_group>
    <arm_group_label>b.i.d.RT</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>b.i.d.RT (45Gy in 30 fractions) to the chest and four cycles of etoposide and cisplatin</description>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>q.d. RT</intervention_name>
    <description>65 Gy in 26 fractions</description>
    <arm_group_label>q.d. RT</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>b.i.d.RT</intervention_name>
    <description>45 Gy in 30 fractions</description>
    <arm_group_label>b.i.d.RT</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Pathologic confirmation of SCLC. Imaging studies' confirmation of limited stage.

          -  No previous chest radiotherapy, chemotherapy or biotherapy.

          -  Patients have measurable or evaluable lesions based on the Response Evaluation
             Criteria in Solid Tumors (RECIST) criteria.

          -  White blood cell count ≥4×109 /L, platelet count≥100×109 /L, hemoglobin ≥100 g /L;
             serum creatinine and total bilirubin 1.5 times or less the upper limits of normal
             (ULN), aspartate aminotransferase two times or less the ULN.

          -  Eastern Cooperative Oncology Group (ECOG) performance status 0-1.

          -  Weight loss ≤10% within the past 3 months.

          -  Forced expiratory volume in 1 s ＞1 L.

        Exclusion Criteria:

          -  Previous or recent another malignancy.

          -  A myocardial infarction within 6 months or had uncontrolled congestive heart failure,
             uncontrolled arrhythmia.

          -  Malignant pleural or pericardial effusion.

          -  Pregnant or Lactating.

          -  Weight loss &gt;10% within the past 3 months.

          -  Drug addiction, long-term alcohol abuse and AIDS patients.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hui Liu, Professor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Sun yat-sen universtiy cancer center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Bo Qiu, Attending</last_name>
    <phone>+86-020-87343031</phone>
    <email>qiubo@sysucc.org.cn</email>
  </overall_contact>
  <location>
    <facility>
      <name>Sun yat-sen university cancer center</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bo Qiu, Attending</last_name>
      <phone>+86-020-87343031</phone>
      <email>qiubo@sysucc.org.cn</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <reference>
    <citation>Kong FM, Lally BE, Chang JY, Chetty IJ, Decker RH, Ginsburg ME, Kestin LL, Langer CJ, Movsas B, Videtic GM, Willers H, Rosenzweig KE; Expert Panel on Radiation Oncology-Lung. ACR Appropriateness Criteria® radiation therapy for small-cell lung cancer. Am J Clin Oncol. 2013 Apr;36(2):206-13. doi: 10.1097/COC.0b013e31827e5523. Review.</citation>
    <PMID>23511336</PMID>
  </reference>
  <reference>
    <citation>Socinski MA, Bogart JA. Limited-stage small-cell lung cancer: the current status of combined-modality therapy. J Clin Oncol. 2007 Sep 10;25(26):4137-45. Review.</citation>
    <PMID>17827464</PMID>
  </reference>
  <reference>
    <citation>Turrisi AT 3rd, Kim K, Blum R, Sause WT, Livingston RB, Komaki R, Wagner H, Aisner S, Johnson DH. Twice-daily compared with once-daily thoracic radiotherapy in limited small-cell lung cancer treated concurrently with cisplatin and etoposide. N Engl J Med. 1999 Jan 28;340(4):265-71.</citation>
    <PMID>9920950</PMID>
  </reference>
  <reference>
    <citation>Chen GY, Jiang GL, Wang LJ, Qian H, Fu XL, Yang H, Wu KL, Zhao S. Cisplatin/etoposide chemotherapy combined with twice daily thoracic radiotherapy for limited small-cell lung cancer: a clinical phase II trial. Int J Radiat Oncol Biol Phys. 2005 Jan 1;61(1):70-5.</citation>
    <PMID>15629596</PMID>
  </reference>
  <reference>
    <citation>Hu X, Bao Y, Zhang L, Guo Y, Chen YY, Li KX, Wang WH, Liu Y, He H, Chen M. Omitting elective nodal irradiation and irradiating postinduction versus preinduction chemotherapy tumor extent for limited-stage small cell lung cancer: interim analysis of a prospective randomized noninferiority trial. Cancer. 2012 Jan 1;118(1):278-87. doi: 10.1002/cncr.26119. Epub 2011 May 19.</citation>
    <PMID>21598237</PMID>
  </reference>
  <reference>
    <citation>Choi NC, Herndon JE 2nd, Rosenman J, Carey RW, Chung CT, Bernard S, Leone L, Seagren S, Green M. Phase I study to determine the maximum-tolerated dose of radiation in standard daily and hyperfractionated-accelerated twice-daily radiation schedules with concurrent chemotherapy for limited-stage small-cell lung cancer. J Clin Oncol. 1998 Nov;16(11):3528-36.</citation>
    <PMID>9817271</PMID>
  </reference>
  <reference>
    <citation>Roof KS, Fidias P, Lynch TJ, Ancukiewicz M, Choi NC. Radiation dose escalation in limited-stage small-cell lung cancer. Int J Radiat Oncol Biol Phys. 2003 Nov 1;57(3):701-8.</citation>
    <PMID>14529774</PMID>
  </reference>
  <reference>
    <citation>Miller AA, Wang XF, Bogart JA, Hodgson LD, Rocha Lima CM, Radford JE, Vokes EE, Green MR; Cancer and Leukemia Group B (CALGB). Phase II trial of paclitaxel-topotecan-etoposide followed by consolidation chemoradiotherapy for limited-stage small cell lung cancer: CALGB 30002. J Thorac Oncol. 2007 Jul;2(7):645-51.</citation>
    <PMID>17607121</PMID>
  </reference>
  <reference>
    <citation>Bogart JA, Herndon JE 2nd, Lyss AP, Watson D, Miller AA, Lee ME, Turrisi AT, Green MR; Cancer and Leukemia Group B study 39808. 70 Gy thoracic radiotherapy is feasible concurrent with chemotherapy for limited-stage small-cell lung cancer: analysis of Cancer and Leukemia Group B study 39808. Int J Radiat Oncol Biol Phys. 2004 Jun 1;59(2):460-8.</citation>
    <PMID>15145163</PMID>
  </reference>
  <reference>
    <citation>Liao ZX, Komaki RR, Thames HD Jr, Liu HH, Tucker SL, Mohan R, Martel MK, Wei X, Yang K, Kim ES, Blumenschein G, Hong WK, Cox JD. Influence of technologic advances on outcomes in patients with unresectable, locally advanced non-small-cell lung cancer receiving concomitant chemoradiotherapy. Int J Radiat Oncol Biol Phys. 2010 Mar 1;76(3):775-81. doi: 10.1016/j.ijrobp.2009.02.032. Epub 2009 Jun 8.</citation>
    <PMID>19515503</PMID>
  </reference>
  <reference>
    <citation>Shirvani SM, Juloori A, Allen PK, Komaki R, Liao Z, Gomez D, O'Reilly M, Welsh J, Papadimitrakopoulou V, Cox JD, Chang JY. Comparison of 2 common radiation therapy techniques for definitive treatment of small cell lung cancer. Int J Radiat Oncol Biol Phys. 2013 Sep 1;87(1):139-47. doi: 10.1016/j.ijrobp.2013.05.040.</citation>
    <PMID>23920393</PMID>
  </reference>
  <reference>
    <citation>Xia B, Chen GY, Cai XW, Zhao JD, Yang HJ, Fan M, Zhao KL, Fu XL. Is involved-field radiotherapy based on CT safe for patients with limited-stage small-cell lung cancer? Radiother Oncol. 2012 Feb;102(2):258-62. doi: 10.1016/j.radonc.2011.10.003. Epub 2011 Nov 5.</citation>
    <PMID>22056536</PMID>
  </reference>
  <reference>
    <citation>Murray N, Coy P, Pater JL, Hodson I, Arnold A, Zee BC, Payne D, Kostashuk EC, Evans WK, Dixon P, et al. Importance of timing for thoracic irradiation in the combined modality treatment of limited-stage small-cell lung cancer. The National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol. 1993 Feb;11(2):336-44.</citation>
    <PMID>8381164</PMID>
  </reference>
  <reference>
    <citation>Giuliani ME, Lindsay PE, Sun A, Bezjak A, Le LW, Brade A, Cho J, Leighl NB, Shepherd FA, Hope AJ. Locoregional failures following thoracic irradiation in patients with limited-stage small cell lung carcinoma. Radiother Oncol. 2012 Feb;102(2):263-7. doi: 10.1016/j.radonc.2011.12.009. Epub 2012 Jan 28.</citation>
    <PMID>22285072</PMID>
  </reference>
  <reference>
    <citation>Fan TY, Xing J, Lu J, Liu TH, Xu M, Zhang YJ, Shao Q, Li JB, Yu JM. Phase I/II study of induction chemotherapy plus concurrent chemotherapy and SMART-IMRT-based radiotherapy in locoregionally-advanced nasopharyngeal cancer. Oncol Lett. 2013 Mar;5(3):889-895. Epub 2013 Jan 15.</citation>
    <PMID>23426016</PMID>
  </reference>
  <reference>
    <citation>Yee D, Hanson J, Butts C, Reiman A, Joy A, Smylie M, Fenton D, Chu Q, Roa W. Phase I dose escalation trial of hypofractionated limited-field external beam thoracic radiotherapy for limited-stage small cell carcinoma of the lung. Radiother Oncol. 2010 Jul;96(1):78-83. doi: 10.1016/j.radonc.2010.05.013. Epub 2010 Jun 11.</citation>
    <PMID>20542346</PMID>
  </reference>
  <verification_date>March 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 9, 2015</study_first_submitted>
  <study_first_submitted_qc>January 13, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 14, 2015</study_first_posted>
  <last_update_submitted>April 15, 2017</last_update_submitted>
  <last_update_submitted_qc>April 15, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">April 18, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Sun Yat-sen University</investigator_affiliation>
    <investigator_full_name>Hui Liu</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>Small cell lung cancer</keyword>
  <keyword>Radiotherapy</keyword>
  <keyword>Dose fractionation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Small Cell Lung Carcinoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cisplatin</mesh_term>
    <mesh_term>Etoposide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

